BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
2/24/2025 9:25:50 AM | Browse: 55 | Download: 99
 |
Received |
|
2024-08-31 05:40 |
|
Peer-Review Started |
|
2024-09-05 05:52 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2024-11-23 05:41 |
|
Revised |
|
2024-12-04 05:41 |
|
Second Decision |
|
2025-01-10 02:35 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2025-01-10 07:12 |
|
Articles in Press |
|
2025-01-10 07:12 |
|
Publication Fee Transferred |
|
2024-12-17 15:42 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2025-02-12 01:27 |
|
Publish the Manuscript Online |
|
2025-02-24 09:25 |
| ISSN |
1948-9366 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Surgery |
| Manuscript Type |
Case Report |
| Article Title |
Lung metastasis following temporary discontinuation of lenvatinib and tislelizumab in hepatocellular carcinoma: A case report
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Chen-Dong Wang, Run-Dong Liu, Ming-Jie Liu and Jia Song |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Jia Song, PhD, Hepatic Surgery Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1095 Jiefang Avenue, Wuhan 430022, Hubei Province, China. tjhsongjia@hust.edu.cn |
| Key Words |
Hepatocellular carcinoma; Hepatic arterial infusion chemotherapy; Lenvatinib; Tislelizumab; Conversion therapy; Case report |
| Core Tip |
In recent years, targeted therapies, immunotherapies with immune checkpoint inhibitors, and localized interventions have effectively managed advanced or non-resectable hepatocellular carcinoma (HCC). Despite these advances, few studies have addressed the crucial need for management strategies during the perioperative period for patients with HCC. To our knowledge, this is the first report to illuminate the potential risk of disease progression and lung metastasis after the temporary cessation of targeted therapy with lenvatinib and immunotherapy with tislelizumab. This finding reveals the importance of refining treatment protocols to reduce the risks of recurrence and metastasis. |
| Publish Date |
2025-02-24 09:25 |
| Citation |
<p>Wang CD, Liu RD, Liu MJ, Song J. Lung metastasis following temporary discontinuation of lenvatinib and tislelizumab in hepatocellular carcinoma: A case report. <i>World J Gastrointest Surg</i> 2025; 17(3): 100951</p> |
| URL |
https://www.wjgnet.com/1948-9366/full/v17/i3/100951.htm |
| DOI |
https://dx.doi.org/10.4240/wjgs.v17.i3.100951 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
